This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
ObjectiveThe aim of this study was to investigate the impact of preprocedural anticoagulation on the incidence of silent cerebral embolisms (SCEs) assessed by magnetic resonance imaging (MRI) after catheter ablation of atrialfibrillation (AF) in patients with low thromboembolic risk.Methods and resultsA total of 141 patients with AF who were identified (..)
BackgroundNon-valvular atrialfibrillation (NVAF) significantly increases ischemic stroke and systemic embolism (SE) risks. Despite the proven efficacy of oral anticoagulants (OAC) in reducing these risks, their underutilization highlights a gap in clinical practice.
BackgroundNonvitamin K oral anticoagulants prevent stroke and systemic embolism in patients with nonvalvular atrialfibrillation. Our analysis included 22 568 patients with nonvalvular atrialfibrillation (aged 75.7 years; 51.2%
Artificial intelligence (AI)-enabled sinus rhythm (SR) electrocardiogram (ECG) interpretation can aid in identifying undiagnosed paroxysmal atrialfibrillation (AF) in patients with embolic stroke of undetermined source (ESUS).
A randomized trial of the factor XIa inhibitor asundexian was stopped early owing to a higher incidence of stroke or systemic embolism than with apixaban therapy among patients with atrialfibrillation.
Anticoagulation is the mainstay of stroke prevention in appropriate patients with atrialfibrillation. An investigational class of agents which inhibit Factor XI have shown promise in pre-clinical and early clinical trials to significantly minimize bleeding while maintaining efficacy against stroke and systemic embolism.
Background Covert atrialfibrillation (AF) is a predominant aetiology of embolic stroke of undetermined source (ESUS). Evidence suggested that AF is more frequently detected by implantable loop recorder (ILR) than by conventional monitoring.
Pulmonary embolism (PE) and atrialfibrillation (AFib) frequently coexist, with AFib increasing the risk of thromboembolic events such as PE. The combination of these conditions is associated with worse clinical outcomes, higher mortality, and increased healthcare burden.
Cancer, atrialfibrillation (AF) and coronary artery disease share some common factors and interact with each other, such as obesity, aging, diabetes, and inflammation, but the potential specific mechanism is still unclear. A growing number of studies have elucidated the association between cancer and CVD.
male with pertinent past medical history including Atrialfibrillation, atrial flutter, cardiomyopathy, Pulmonary Embolism, and hypertension presented to the Emergency Department via ambulance for respiratory distress and tachycardia. Of course, this is NOT atrial fib, but rather PSVT, and so adenosine should work.
BackgroundLeft atrial appendage occlusion (LAAO) was associated with a high incidence of procedurerelated silent cerebral embolism (SCE). There are limited data regarding the longterm cognitive trajectory of patients undergoing LAAO.
A magnetic resonance imaging (MRI) pattern suggestive of an embolic etiology has been described but, to date, there are no uniformly accepted criteria. Aim The purpose of the study is to describe MRI features of ischemic cerebral lesions occurring after transcatheter ablation of atrialfibrillation (AF).
Atrialfibrillation (AF) has been known as a main cause of embolic stroke. Well-chosen candidate to be anticoagulated should be critical for secondary prevention in patients with embolic stroke with undetermined source (ESUS).
Cancer patients have a higher risk of atrialfibrillation (AF) than general population, however, the link between cancer and AF is not fully understood. The association between AF detected by implanted cardiac implantable electronic devices (CIEDs) and the incidence of embolic stroke has been reported.
Patients with atrialfibrillation, particularly older patients, are frequently at a high risk of bleeding. In patients with atrialfibrillation, abelacimab reduced rates of bleeding relative to rivaroxaban regardless of bleeding risk, with greater absolute safety benefit in those at higher bleeding risk.
BackgroundDespite proven efficacy and safety of direct oral anticoagulants (DOACs) over warfarin in patients with atrialfibrillation (AF), data on patients with AF and valvular heart disease remain scarce. The primary effectiveness outcomes were ischemic stroke or systemic embolism, and bleeding for safety.
Polygenic risk score (PRS) might be useful in predicting atrialfibrillation (AF)-related stroke/systemic embolsim (SSE) before diagnosis of clinical AF.
Atrialfibrillation (AF) is a common cause of embolic stroke and strongly associated with the development of heart failure with preserved ejection fraction (HFpEF). Left atrial disease is commonly considered as central to the pathophysiology of these conditions.
Background:A considerable portion of patients with embolic stroke of unknown source(ESUS)are later found to have occult atrialfibrillation (AF). Stroke, Volume 55, Issue Suppl_1 , Page ATP223-ATP223, February 1, 2024.
In patients with embolic stroke of undetermined source (ESUS), the detection of atrialfibrillation (AF) entails a treatment change and, consequently, a drastic reduction in morbidity, mortality, and stroke recurrence rate.
BackgroundThrombocytopenia is often associated with adverse outcomes in patients with atrialfibrillation. ResultsA total of 12 studies included 73,824 patients with atrialfibrillation (average age: 72.67, males: 42,275, 57.3%), among them, there were 7,673 patients combined with thrombocytopenia.
Silent cerebral events (SCEs) have been identified in 20% of patients undergoing catheter ablation for atrialfibrillation (AF). However, the incidence of micro embolic signals (MESs) during PFA for AF remains unexplored. Pulsed-field ablation (PFA) utilizes three types of catheters: FARAPULSE, PulseSelect, and VARIPULSE.
Asymptomatic cerebral emboli (ACE) can occur in patients undergoing an atrialfibrillation (AF) ablation, and has been studied extensively for radiofrequency ablation procedures. However, recent trials using PFA catheters have paused or terminated early due to concerns for cerebral embolism or ischemic stroke.
Atrialfibrillation(AF) is associated with increased risk of embolic stroke and heart failure hospitalizations in patients with hypertrophic cardiomyopathy(HCM).
In a randomized trial involving patients with subclinical (typically asymptomatic) atrialfibrillation, apixaban led to a lower risk of stroke or systemic embolism than aspirin but a higher risk of major bleeding.
Clinical, imaging, and genetic markers in combinations might be useful for risk assessment of atrialfibrillation (AF) and related stroke/systemic embolsim (SSE).
Atrialfibrillation (AF) confers significant morbidity and mortality in the form of embolic stroke, heart failure, cognitive decline, and recurrent hospitalizations as well as health care costs.1
Embolic stroke of undetermined source (ESUS), a subset of cryptogenic stroke, which excludes small-vessel disease cause, has a high recurrence rate and is a subgroup in need of further characterisation and treatment optimisation. AF detection rates with implantable cardiac monitoring (ICM) following cryptogenic stroke are >12% at 12 months.
Mass screening for atrialfibrillation using ECG together with heart failure biomarker does not prevent ischemic stroke or systemic embolism (blood clot) in older adults aged 75–76 years over 5 years follow-up, according to late breaking research presented in a Hot Line Session at this year's ESC Congress 2024 in London, UK (30 Aug–2 Sept).
Patients undergoing atrialfibrillation (AFib) ablation who were not properly anticoagulated and did not undergo preprocedural transesophageal echocardiogram (TEE) were significantly more likely to suffer from transient ischemic attack (TIA) or pulmonary embolism (PE).
Nonvalvular atrialfibrillation is a common rhythm disorder of middle-aged to older adults that can cause ischemic strokes and systemic embolism. Stroke, Volume 55, Issue 1 , Page 214-225, January 1, 2024.
Bernard's Heart & Vascular Center , Jonesboro, Arkansas) mark a significant milestone in the pursuit of innovative solutions for non-valvular atrialfibrillation (NVAF) treatment. Patients with NVAF deemed appropriate for LAAX to reduce the risk of stroke and systemic embolism, will participate in this research effort.
BackgroundThere are limited data on the efficacy and safety of direct oral anticoagulants (DOACs) in patients with atrialfibrillation with significant tricuspid regurgitation (TR), which can lead to hepatic dysfunction and intestinal malabsorption. The median follow‐up duration was 2.4 1.06];P=0.11).
Cryoablation for atrialfibrillation is a widely used technique for pulmonary vein isolation. Known complications associated with cryoablation include tamponade, phrenic nerve injury, stroke, pulmonary embolism, pulmonary vein stenosis, and atrioesophageal fistulas.
Abnormal conduction, structure and function of the atrial myocardium predispose to atrialfibrillation (AF) and stroke. Usefulness of electrocardiographic (ECG) indices in predicting stroke or systemic embolism (SSE) in patients undergoing cardioversion for AF remains unknown, especially in those at low estimated risk.
Background Amiodarone is an established treatment for atrialfibrillation (AF) but might interfere with the metabolism of apixaban or warfarin. Exploratory outcomes included ischaemic stroke/systemic embolism and all-cause/cardiovascular (CV) mortality. Methods Retrospective observational study using Swedish health registers.
BackgroundThe clinical utility of the polygenic risk score in predicting cardiovascular events in patients with atrialfibrillation (AF) has not yet been established. years), the incidence rates of ischemic stroke or systemic embolism, myocardial infarction, and heart failure hospitalization were 0.83, 0.42, and 0.61
Single-nucleotide variants (SNVs) of ABCB1 gene encoding glycoprotein P might be connected with increased or decreased levels of direct oral anticoagulants (DOAC), and therefore with DOAC-related adverse bleeding or embolism. The PLINK software was used to compare the differences between the groups.
The baseline CHA2DS2-VASc score helped to identify patient with subclinical atrialfibrillation (SCAF) in whom the benefit for reducing the risk of stroke and systemic embolism (SE) with an oral anticoagulant (OAC) was greater than the risk of increased major bleeding, according to a subgroup analysis from the ARTESiA study presented at Heart Rhythm (..)
Affecting 60 million people worldwide 1 , the prevalence of atrialfibrillation (AFib) is expected to increase by 60% by 2050 due to an aging population and rising cardiometabolic risk factors 2. In addition, the Centers for Disease Control and Prevention (CDC) estimates that more than 12 million Americans will have AFib by 2030 3.
Edoxaban was comparable to warfarin in preventing stroke or systemic embolism and intracardiac thrombus in patients with non-valvular atrialfibrillation (AFib) within three months after bioprosthetic valve surgery, based on preliminary findings from the ENBALV trial presented at AHA 2024.
Ian Stiell on atrialfibrillation rate vs rhythm control controversy, Justin Morgenstern on peripheral vasopressors: safe or unsafe? Michelle Klaiman, Taryn Lloyd on motivational interviewing that makes a difference to patient's lives.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
52 
Let's personalize your content